Known as the “king of cancers,” pancreatic ductal adenocarcinoma (PDAC) is highly malignant, rapidly progressive, and has a dire prognosis. It has long been a major challenge in solid tumor treatment. For most patients with advanced metastatic pancreatic cancer, after first-line chemotherapy, subsequent treatment options are scarce and survival is extremely short. There is an urgent clinical need for breakthrough targeted therapies.
At the Plenary Session of the 2026 ASCO Annual Meeting, Prof. Brian M. Wolpin from Dana-Farber Cancer Institute and Harvard Medical School presented the final core data of the global phase 3 RASolute 302 trial (Abstract LBA5). The results showed that daraxonrasib, a novel RAS(ON) multi-selective inhibitor, achieved a breakthrough benefit in previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC) — doubling survival and reducing the risk of death by 60%. It also demonstrated a favorable safety profile and improved quality of life, achieving positive results across all endpoints and potentially reshaping the later-line treatment landscape for advanced pancreatic cancer.

Fighting for Survival: The Clinical Challenge of Later-Line Treatment in Advanced Pancreatic Cancer
Pancreatic cancer is called the “king of cancers” for good reason. Currently, standard first-line chemotherapy offers limited benefit, and once the disease progresses, second-line options are even more scarce — conventional chemotherapy yields a median progression-free survival (PFS) of only 3-4 months and a median overall survival (OS) of just 6-7 months.
What is even more frustrating is that although over 90% of pancreatic cancers harbor activating RAS mutations (most commonly KRAS G12D, G12V, and G12R), for many years no RAS-targeted drug has been approved for pancreatic cancer. KRAS G12C inhibitors have made progress in lung cancer but benefit less than 1% of pancreatic cancer patients.
That is, until Daraxonrasib emerged. Daraxonrasib is a novel RAS(ON) multi-selective inhibitor that precisely binds to the GTP-bound activated RAS protein, broadly covering wild-type RAS and various mutant subtypes including KRAS and NRAS G12, G13, and Q61. Previous phase 1/2 studies had already shown promising preliminary efficacy and manageable safety in advanced pancreatic cancer, laying a solid foundation for this phase 3 study.
RASolute 302 Study Design: A Global, High-Quality Phase 3 Confirmatory Trial
This was a global, randomized, controlled phase 3 trial conducted across 59 centers in Asia, Europe, and North America.
Treatment Arms and Randomization: 500 enrolled patients were randomized 1:1 to:
· Daraxonrasib arm: 300 mg once daily orally
· Chemotherapy control arm: Standard second-line chemotherapy chosen by investigators and patients (mainly nab-paclitaxel + gemcitabine or fluoropyrimidine-based regimens)
At the data cutoff in February 2026, the results were clear:
1. OS – Nearly doubled benefit
In the RAS G12-mutant population, median OS was 13.2 months in the Daraxonrasib arm vs. 6.6 months in the chemotherapy arm, with a hazard ratio (HR) of 0.40 (P=5.9×10⁻¹⁰). In the overall population (including other rare mutations and patients with no detectable mutations), the results were nearly identical: 13.2 months vs. 6.7 months, HR also 0.40 (P=4.6×10⁻¹¹).
These P-values, on the order of 10⁻¹¹, are exceptionally rare in oncology trials.
2. PFS and Objective Response Rate (ORR) – Comprehensive advantages
In the overall population, the ORR was 31.6% in the Daraxonrasib arm vs. 11.2% in the chemotherapy arm. PFS was also significantly improved, with HRs of 0.45 and 0.49.
3. Subgroup analyses – Benefit across the board
Regardless of age, ECOG performance status, RAS mutation status, prior chemotherapy regimen, or presence of baseline liver metastases, all subgroups consistently showed superiority of Daraxonrasib over chemotherapy. These consistent subgroup results further reinforce the robustness of the findings.
4. Safety – Consistent with prior profile, no new signals
Median treatment exposure was 6.2 months in the Daraxonrasib arm (vs. 1.5-3.2 months in the chemotherapy arm), with a median dose intensity of 93%. The most common grade ≥3 adverse events (AEs) were rash, diarrhea, and stomatitis. Discontinuation due to treatment-related adverse events (TRAEs) occurred in only 1% of patients in the Daraxonrasib arm vs. 11% in the chemotherapy arm. The most common TRAEs leading to dose reduction were rash and stomatitis in the Daraxonrasib arm, vs. myelosuppression and neuropathy in the chemotherapy arm.
5. Quality of life – Living longer, living better
Patient-reported outcomes showed that Daraxonrasib significantly delayed time to worsening of pain and time to deterioration of global health status/quality of life (HR for pain worsening = 0.51; HR for QoL deterioration = 0.60). For pancreatic cancer, a disease often accompanied by severe pain, this finding is particularly valuable.
Conclusion
In his concluding remarks, Prof. Wolpin firmly announced: Daraxonrasib should become the new standard of care for previously treated metastatic pancreatic cancer. This is not a mere formality. For a long time, later-line treatment of advanced pancreatic cancer has relied on conventional chemotherapy, with prominent efficacy bottlenecks and significant toxicities, lacking an effective, precise, and safe targeted therapy. The robust positive results of the RASolute 302 trial have finally broken this clinical deadlock.
In the future, as RAS targeting mechanisms are further explored and combination strategies are developed, RAS inhibitors are expected to move to earlier lines of therapy, reshaping the entire treatment landscape of pancreatic cancer and creating survival miracles for more patients with advanced malignancies.